Mucorales species are deadly opportunistic fungi with a rapidly invasive nature. A rare disease, mucormycosis is most commonly reported in patients with diabetes mellitus, because the favorable carbohydrate-rich environment allows the Mucorales fungi to flourish, especially in the setting of ketoacidosis. However, case reports over the past 20 years show that a growing number of cases of mucormycosis are occurring during treatment following bone marrow transplants (BMT) and hematological malignancies (HM) such as leukemia and lymphoma. This is due to the prolonged treatment of these patients with steroids and immunosuppressive agents. Liposomal amphotericin B treatment and posaconazole are two pharmacologic agents that seem to be effective against mucormycosis, but the inherently rapid onset and course of the disease, in conjunction with the difficulty in correctly identifying it, hinder prompt institution of appropriate antifungal therapy. This review of the literature discusses the clinical presentation, diagnosis, and treatment of mucormycosis among the BMT and HM populations.
Mucormycosis is a rare and rapidly progressive opportunistic fungal infection that most often presents among patients with diabetes mellitus, immunodeÞ ciency, neutropenia, iron overload, and severe burns. There has been a reported rise in mucormycosis among patients with hematological malignancies (HM), e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML), and in bone marrow transplant (BMT) recipients due to the neutropenia and immunodeÞ ciency associated with chemotherapy and posttransplant steroid treatment. [1] [2] [3] Due to the difÞ culty in early diagnosis and the especially detrimental course in leukemia and BMT patients, there is an urgent need to develop new methods for the rapid diagnosis and treatment of this disease.
Though a relatively uncommon fungal infection in comparison with candidiasis and aspergillosis, mucormycosis cases have been on the rise over the past decade. [4] One study indicates that the increase is due to the the increased use of chemotherapy and steroids, which is associated with a prolonged immunocompromised state. [5] Mucormycosis can be caused by any fungal species within the Mucorales order. This mold infection is also referred to as zygomycosis or phycomycosis in the literature.
The most commonly seen genera in mucormycosis cases are Rhizopus, Rhizomucor, Mucor, and Absidia. [6, 7] Mucormycosis is unique among the Þ lamentous fungi because of its capacity to cause disease in a much wider human population than the other opportunistic fungi.
ETIOLOGY
Mucorales, Þ rst described in 1885 by Paltauf, [8] is the largest and most widely studied order of the fungal class Zygomycete. The most commonly seen genera in mucormycosis are from the Mucoraceae family; recently, however, an increasing number of Cunninghamella infections from the Cunninghamellaceae family are also being reported. Figure 1 shows the classiÞ cation of the clinically relevant families, genera, and species of the Mucorales order.
Mucorales fungi are characterized by fast-growing fibrous mycelium and thin-walled aseptate or hyposeptate hyphae that measure 10-20 µm in width. Right-angled branching is also seen as it rapidly grows within the host tissue. As the hyphae grow they invade the blood vessels and result in tissue infarction. [7, 9] This ultimately leads to tissue necrosis and vessel thrombosis. [7, 10] Although it is an uncommon infection in the general population, exposure to Mucorales is common. Most species are saprotrophic, obtaining their nutrients from dead organic matter, and grow in soil, fruit, bread, and plants. Some are characterized as parasites of animals, plants, and other fungi. Mucormycosis infection in humans is usually acquired through airborne fungal spores. [7, 10] The number of spores rapidly increases in carbohydrate-rich environments. Increased availability of soluble iron in the host is also believed to play a role in promoting Mucorales growth, especially in patients receiving deferoxamine iron chelation therapy, where the deferoxamine acts as a siderophore so the fungi may utilize the iron in its growth. [11] [12] [13] For optimal growth in humans, Mucorales fungi require the host to have decreased levels of neutrophils. Neutrophils are the key defense against the fungi in the host tissue. In healthy humans with intact immune systems, neutrophils phagocytize these pathogens. However, in neutropenic individuals, the unregulated pathogens proliferate in the host tissue and infection ensues. Neutropenia is often a side effect of chemotherapy in cancer patients or of the malignancy itself and is also seen in immunocompromised individuals. The vast majority of patients with mucormycosis are neutropenic, with neutrophil counts usually below 0.5 × 10 9 /l. The reference range is 1.8 × 10 9 /l to 7 × 10 9 /l.
EPIDEMIOLOGY
The literature reports an increase in mucormycosis, as compared to invasive aspergillosis, among immunocompromised patients over the last 2 decades. [14] Marr et al., based on their study of 5589 transplant patients at the Fred Hutchinson Cancer Center, report that the number of cases of mucormycosis have more than doubled from 1985-1989 to 1995-1999 . [1] Rhizopus are the most commonly isolated species among these patients. Less common, but increasingly frequent in the general population, is the Cunninghamella bertholletiae species. [15, 16] No studies have indicated any bias for or against any speciÞ c gender, race, or age.
According to one study, the annual incidence of mucormycosis in the general population is 1.7 cases for every 1 million individuals, which amounts to approximately 500 affected Americans each year. [17] However, this is likely to be an underestimate because of the low rate (23-50%) of antemortem diagnosis [18] and also because a large number of cases remain undiagnosed due to the decline in autopsies in the United States and Europe from around 60% in the 1960s to around 10% at present. [19] [20] [21] Although most cases of mucormycosis are seen in patients with unregulated diabetes mellitus, the numbers have been decreasing over the past 20 years and, instead, an increasing numbers of individuals with HM are presenting with the infection. Recent studies indicate that 1-3% of BMT patients present with mucormycosis. [10, 22, 23] The incidence of mucormycosis in adult leukemia patients is reported at around 2%. [24] Those leukemia patients who have developed neutropenia due to chemotherapy or the malignancy are most susceptible to the fungus. Mortality rates in patients with HM who have mucormycosis is greater than 50%. [3, 25] [25] ; the authors reported a mortality rate of 55% and a successful treatment rate of 40% in their series. [25] 
CLINICAL PRESENTATION
Mucormycosis commonly presents in Þ ve forms: it may affect the pulmonary, rhinocerebral, gastrointestinal, cutaneous, or the central nervous systems. [7] Dissemination may also occur due to the highly invasive nature of Mucorales. [7] Dissemination is a term used to describe an infection that affects two or more noncontiguous organ systems. Of the Þ ve forms, pulmonary and rhinocerebral are the most common. Disseminated mucormycosis affects the lungs and brain most often, with the infection usually originating in the lungs. [6] Our review of the case reports in the literature suggest that among HM and BMT patients the pulmonary presentation of mucormycosis is most common, followed by the disseminated form. A study by Lee 
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Figure 1: Taxonomy of the most clinically relevant Mucorales species categorized by family and genus. [75] et al. of 87 pulmonary mucormycosis patients indicated that those with HM comprised 32% of the cases; the majority (56%) of the cases were those with diabetes mellitus. [5] Table 2 details the different features associated with each of the Þ ve forms of the infection and the common differential diagnoses for each.
The most common symptom in pulmonary mucormycosis is a high-grade fever (> 39°C) that does not subside despite the administration of antibiotics. [5, 16, 24, 26, 32, 36, [42] [43] [44] [45] [46] [47] Coughing and respiratory distress are also seen. Auscultation of these patients' chests may reveal moist rales and pleural friction rubs. Pleuritic chest pain is often present in these patients. Oral thrush may also appear. Computed tomography of the chest may show illdeÞ ned round densities, halo and lobar expansion, and pleural inÞ ltrates. Patchy consolidations and cavitations may also be seen on chest radiography.
Cases of rhinocerebral mucormycosis present with facial pain, periorbital cellulitis, proptosis, visual deÞ ciencies, black necrotic lesions and discharge from the nasal and palatal mucosa, and fever. [38, 48, 49] Biopsy reveals fungal hyposeptated hyphae consistent with Mucorales. Most patients with this form of mucormycosis have diabetes mellitus [5] ; it is not very common among BMT and HM patients. Barron et al. [29] Hodgkin's Rhinocerebral Rhizopus Nasal wash culture, histology S lymphoma 2002 Cloughley et al. [30] Gastrointestinal mucormycosis presents with features similar to that seen in bowel obstruction. Tenderness on palpation, with or without the presence of a mass, and hepatomegaly or splenomegaly have been reported. [23, 34] This form of the infection is seen most commonly among malnourished adults and in individuals with underlying gastrointestinal disease or abnormalities such as kwashiorkor, colitis, typhoid, or pellagra. [2] Cutaneous involvement by mucormycosis has been reported as presenting with black necrotic lesions, most often on the face and extremities. Many of the cases of cutaneous mucormycosis reported in BMT and HM patients seem to have been caused by A corymbifera. The site of the lesion may be where catheters are placed. [40] Reports in the literature suggest that due to the superÞ cial nature of these infections, early diagnosis and surgical debridement with skin grafting give highly favorable outcomes. [23, 30, 33, 40] Brain mucormycosis is not common by itself; CNS involvement is usually a result of dissemination of the fungal infection from pulmonary or rhinocerebral sources. [37] Paterson et al. have reported a CML patient in whom mucormycosis spread through the ear to invade cerebral tissue; the patient died 15 days post-BMT. [35] 
DIAGNOSIS
Mucormycosis can be a fatal infection and early diagnosis and treatment are of extreme importance for successful eradication of the infection and for patient survival. Differential diagnoses may be varied due to the different clinical presentations and organ systems involved. The most commonly employed technique for differentiating between mucormycosis and other diseases is a histopathological study. [50] However, due to the frequently encountered difÞ culty in distinguishing Mucorales from other Þ lamentous fungi, [9] more sophisticated diagnostic techniques are emerging and being evaluated. A discussion of the various techniques available follows. Table 3 summarizes their general features, issues, and efÞ cacy.
For a deÞ nitive diagnosis of mucormycosis, the histopathological specimen need not be of the isolated fungus, but may be a sample of the necrotic tissue from the site in question. The Grocott-Gomori methenamine silver (GMS) stain is most effective for identifying fungi. However, hematoxylin and eosin, periodic acid-Schiff (PAS), or Calcoß uor White stains may also be used. [2] Invasion of the tissue by fungal hyphae and rightangle branching will be present in mucormycosis specimens. [9] Fungal angioinvasion, perineural invasion, and the presence of neutrophilic inÞ ltrate in the necrotic tissue are also characteristic of mucormycosis. [9] Mucorales are sometimes difÞ cult to distinguish in tissues from other Þ lamentous fungi on histopathological examination. [9] Nevertheless, histopathology continues to be commonly employed for the diagnosis of mucormycosis.
Culture studies often fail to grow Mucorales in mucormycosis patients. Blood cultures are especially known to produce false negative results. The ideal culturing technique is to receive the infarcted tissue and submit it for processing by mincing the tissue with a sterile scalpel and not by grinding it. The syncytial cells of the Mucorales fail to grow in culture if submitted to a grinding procedure, which will produce small fragments devoid of any enclosing septal cell walls. Mucorales grow well on Sabouraud dextrose, brain-heart infusion, or potato dextrose agar incubated at 25-30°C. IdentiÞ cation of saprophytic mold does not conclusively indicate that an infection with that organism has occurred; therefore culture is not usually used alone for diagnosis.
A recent Mayo clinic study using the MicroSeq D2 large-subunit ribosomal DNA sequencing kit to identify Þ lamentous fungi concluded that nucleic acid sequencing using this technique holds much promise, with accurate identiÞ cation possible in under 24 h. [51] However, more work needs to be done to improve its relevance to the more clinically prevalent fungal species. Less than 50% of the Zygomycetes tested in this study were identiÞ ed correctly. Kobayashi et al. recently conducted a study showing 
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Decreased consciousness, ear pain, Cranial nerve palsies, Not as common -system mucormycosis convulsions, paralysis, cranial nerve stroke, otitis externa deÞ cits BMT: BONE MARROW TRANSPLANT; HM: HEMATOLOGICAL MALIGNANCY the usefulness of panfungal PCR on serial serum samples for diagnosing pulmonary mucormycosis caused by Cunninghamella bertholletiae. [45] Rickerts et al. reported the use of a combination of two nested PCR assays to differentiate between Aspergillus and Zygomycetes (which are difÞ cult to tell apart by clinical and radiographic signs) and successfully identiÞ ed the Zygomycetes to the species or genus level. [52] They were able to identify the organism in culture-negative samples as well. Another technique that has been recently developed takes advantage of the sequence variability in the internal transcribed spacer 2 (ITS2) of fungi for identifying Zygomycete isolates to the species level; this is possible because of the signiÞ cantly different sequences between species. [53, 54] At present, serological testing is not recommended for diagnosis due to its investigational status. [55] Only a few reported cases have used antibody testing for mucor IgE in order to diagnose mucormycosis. [56] Susceptibility testing is used to determine a drug's potential effectiveness for eradicating infection and inhibiting growth of the pathogen. One susceptibility testing method commonly used for Aspergillus utilizes ß uorescence-based microplate assays. This method may come into use for Zygomycetes in the future but has not yet been comprehensively evaluated. A recent study by Antachopoulos showed that clinically important Zygomycetes show signiÞ cant metabolic activity in XTT assays even before visual or spectrophotometric evidence of activity becomes apparent. [57] XTT is the tetrazolium salt 2,3-bis{2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide}. The XTT assay is a colorimetric method of quantifying fungal growth by measuring the metabolism of XTT by fungal mitochondrial dehydrogenases. Electron transfer agents such as menadione are also needed for efÞ cient reduction. [57] These XTT assays, performed at 6-12 h post-inoculation, provided results in agreement with the older standard methods of susceptibility testing, which are done 24 h post-inoculation. Several other methods exist for rapid susceptibility testing in Þ lamentous fungi, however many are purely for assessing susceptibility to amphotericin B and require the use of expensive laboratory equipment or potentially hazardous substances. In contrast, XTT assays may also be used for testing susceptibility to other drugs and is a more viable alternative for use in most laboratories.
TREATMENT
Mortality rates among patients with HM who have mucormycosis remain high despite antifungal therapy. Surgical intervention and debridement is the gold standard of treatment for eradicating the infection. [4, 7, 58] However many of the clinical presentations do not allow for such methods of treatment. Favored alternatives for treatment include various amphotericin B formulations and posaconazole, with different Mucorales genera and species showing slight differences in susceptibilities to the drugs. [59] Most cases that have been successfully treated have required approximately 5 weeks of therapy.
There are many similarities in the clinical presentations of aspergillosis and mucormycosis. The ineffectiveness of the drugs used in aspergillosis for the treatment of mucormycosis makes it especially important to establish the diagnoses as early as possible in the course of disease. For leukemia and BMT patients who 
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receive prophylactic antifungal drugs as part of their treatment, it is crucial to distinguish between the different fungal infections as soon as possible after symptoms appear in order to administer the correct antifungal therapy. Early correction of predisposing factors such as neutropenia and immunodeÞ ciency are also important in controlling the progression of the infection.
The most effective treatments for mucormycosis in BMT and leukemia patients are various formulations of amphotericin B combined with posaconazole. [59] Itraconazole is somewhat ineffective against Mucorales, especially against Rhizopus species. [6, 59] there is conflicting data on the efficacy of echinocandins against mucormycosis and the reported cases do not present a strong argument either way. [60, 61] Voriconazole, an effective dr ug in aspergillosis, [62] is not recommended against mucormycosis due to its ineffectiveness both in vitro and in vivo. [22, 46, 59, [63] [64] [65] Not only is voriconazole ineffective in the treatment of mucormycosis, it has also been associated with breakthrough infections of mucormycosis. [22, 63, 64, 66] Several cases have been published where patients with HM were given voriconazole against Aspergillus infection, only to Þ nd that they develop mucormycosis later. These cases showed breakthrough mucormycosis at 9-12 days after voriconazole administration was started as an empiric antifungal treatment in leukemia. Marty et al. also reports breakthrough mucormycosis in stem cell transplant recipients who received voriconazole as prophylactic or empiric therapy. [22] Voriconazole is an effective drug against Aspergillus, Candida, Scedosporium, and Fusarium. [67, 68] The popular utilization of this drug for prophylaxis against common fungal agents allows the Mucorales (which are resistant to it) to emerge unchallenged and infect these highly immunocompromised patients. [66] These Þ ndings emphasize the need for more caution when using voriconazole as a prophylactic agent in this patient population.
Amphotericin B has been the drug of choice against mucormycosis for over 50 years due to its superior effectiveness compared to other therapies. Treatment duration is usually between 3 and 6 weeks and the total dose that needs to be administered ranges from 2.0-4.0 g, depending on the speciÞ c case. [7] Among the different formulations of this drug are liposomal amphotericin B (LAmB) and cochleate-containing amphotericin B (CAmB). LAmB is relatively low in toxicity and does not have many adverse effects, making it the favored choice. Salonen described one leukemia patient in whom LAmB therapy was concurrently administered with chemotherapy.
[26] An allogeneic bone marrow transplantation had been done in this patient and it was possible to prevent relapses of mucormycosis throughout the treatment period by continuing LAmB in conjunction with secondary antifungal prophylaxis. According to Wingard et al., administration of CAmB to treat mucormycosis may not be favorable and may even be toxic due to the high dosage levels and prolonged treatment required. [69] Another lipid formulation of amphotericin B, amphotericin B lipid complex (ABLC), has had success in treating patients with mucormycosis.
Posaconazole is a relatively new drug that appears to be a promising alternative or adjunctive to LAmB administration. [59, 70, 71] Rickerts et al. reported the case of a leukemia patient in whom disseminated mucormycosis was successfully treated with the use of a combination of LAmB and posaconazole without surgical intervention. Other authors have also reported similar success. [62, 72] Many experienced conditions favor combination therapy of posaconazole and lipid formulations of amphotericin B over monotherapy. However, there is no conclusive data yet available to determine if combination therapy is additive, synergistic, or antagonistic.
Another alternative or adjuvant therapy is hyperbaric oxygen (HBO). A study published in 2004 by Garcia-Covarrubias showed 60% survival rate using HBO as an adjuvant therapy to amphotericin B and surgical debridement. [73] A 1994 study of 208 cases by Yohai also supported the improvement in prognosis with the use of HBO. [74] Despite its promising outlook, the literature is still too sparse in this area to make a conclusive case for including HBO as part of the treatment regimen.
CONCLUSION
The high mortality rate among mucormycosis patients calls for an increased index of suspicion and aggressive attempts to diagnose and treat the disease at an early stage. Because of its rarity, mucormycosis is often not included in the differential diagnosis until widespread Mucorales invasion has already taken place in the patient. Its commonplace presence in the environment emphasizes the importance of keeping the wards and hospital instruments free of these opportunistic fungi. Increasing the implementation of promising new diagnostic methods such as PCR nested assays and ITS2 sequencing may help increase the rate of successful Mucorales identiÞ cation in the early stages of infection. However, the new assays await FDA approval for implementation in hospital-based clinical microbiology laboratories. LAmB and posaconazole treatment have helped to treat many cases of mucormycosis. However, despite these advances, the incidence of the infection has risen in recent years, in part due to the use of prolonged chemotherapy and immunosuppressive treatment in HM and BMT patients. Given the increase in cases of breakthrough mucormycosis after general antifungal prophylaxis and the overall increase in cases in this population, anti-Mucorales prophylaxis studies are warranted and should be given due importance, alongside the search for better methods of diagnosis and treatment.
